ArticleTzu chi medical journal
Serum malondialdehyde-modified low-density lipoprotein level is a risk factor for peripheral artery disease in patients with stage 3 to 5 chronic kidney disease.
Article in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Serum malondialdehyde-modified low-density lipoprotein (MDA-LDL) is a biomarker of oxidative burden and lipid peroxidation that contributes to the development of atherosclerotic cardiovascular diseases. In patients with chronic kidney disease (CKD), both traditional and nontraditional factors increase the risk of vascular calcification and peripheral artery disease (PAD). This cross-sectional study explored the link between serum MDA-LDL and PAD in CKD stages 3-5 patients not receiving dialysis. Materials and Methods: Fasting blood specimens and baseline clinical characteristics were collected from CKD stages 3 to 5 patients not receiving dialysis. PAD was diagnosed using ankle-brachial index (ABI), and those with ABI <0.9 were classified into the low ABI group. Serum MDA-LDL levels were quantified with a commercially available enzyme-linked immunosorbent assay kit. Results: Eighteen of the 138 patients (13.0%) had a low ABI. In comparison with the normal ABI group, these patients were significantly older ( Conclusion: Elevated serum MDA-LDL level was an independent risk factor for PAD in those with CKD stages 3-5 not receiving dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.